These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 7584973)
1. The state of the art in antisense research. Wagner RW Nat Med; 1995 Nov; 1(11):1116-8. PubMed ID: 7584973 [No Abstract] [Full Text] [Related]
2. Towards genomic drug therapy with antisense oligonucleotides. Lönnberg H; Vuorio E Ann Med; 1996 Dec; 28(6):511-22. PubMed ID: 9017110 [TBL] [Abstract][Full Text] [Related]
3. Elucidating cell signaling mechanisms using antisense technology. Koller E; Gaarde WA; Monia BP Trends Pharmacol Sci; 2000 Apr; 21(4):142-8. PubMed ID: 10740290 [TBL] [Abstract][Full Text] [Related]
4. Antisense therapeutics: from theory to clinical practice. Pirollo KF; Rait A; Sleer LS; Chang EH Pharmacol Ther; 2003 Jul; 99(1):55-77. PubMed ID: 12804699 [TBL] [Abstract][Full Text] [Related]
5. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Phillips MI Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099 [TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides: promise and reality. Lebedeva I; Stein CA Annu Rev Pharmacol Toxicol; 2001; 41():403-19. PubMed ID: 11264463 [TBL] [Abstract][Full Text] [Related]
7. Antisense oligonucleotides: the state of the art. Aboul-Fadl T Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780 [TBL] [Abstract][Full Text] [Related]
8. Sequence-specific activity of antisense oligonucleotides conjugated to poly (L-lysine) carriers. Degols G; Leonetti JP; Lebleu B Ann N Y Acad Sci; 1992 Oct; 660():331-3. PubMed ID: 1340150 [No Abstract] [Full Text] [Related]
10. Advances in understanding the pharmacological properties of antisense oligonucleotides. Crooke ST Adv Pharmacol; 1997; 40():1-49. PubMed ID: 9217922 [No Abstract] [Full Text] [Related]
11. Rational selection and quantitative evaluation of antisense oligonucleotides. Jayaraman A; Walton SP; Yarmush ML; Roth CM Biochim Biophys Acta; 2001 Aug; 1520(2):105-14. PubMed ID: 11513951 [TBL] [Abstract][Full Text] [Related]
12. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes]. Sommer W; Heilig M Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826 [TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles. Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711 [TBL] [Abstract][Full Text] [Related]
15. RNA learns from antisense. Corey DR Nat Chem Biol; 2007 Jan; 3(1):8-11. PubMed ID: 17173018 [TBL] [Abstract][Full Text] [Related]
16. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs. Wagner A; Bock CT; Fechner H; Kurreck J Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598 [No Abstract] [Full Text] [Related]
17. ENA oligonucleotides as therapeutics. Koizumi M Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767 [TBL] [Abstract][Full Text] [Related]
18. Variations in mRNA content have no effect on the potency of antisense oligonucleotides. Miraglia L; Watt AT; Graham MJ; Crooke ST Antisense Nucleic Acid Drug Dev; 2000 Dec; 10(6):453-61. PubMed ID: 11198929 [TBL] [Abstract][Full Text] [Related]
19. Application of antisense techniques to characterize neuronal ion channels in vitro. Volsen SG; Lambert RC; Maulet Y; De Waard M; Gillard S; Craig PJ; Beattie R; Feltz A Methods Enzymol; 2000; 314():290-310. PubMed ID: 10565021 [No Abstract] [Full Text] [Related]